Last reviewed · How we verify

NCT04499638

Incidence of Complications of Peripheral Venous Access in the Type 2 Diabetic Population

Completed Last updated 25 February 2025
What this trial tests

trial testing Peripheral vascular catheters in Diabetes Mellitus, Type 2 in 350 participants. Completed in 15 May 2021.

Timeline
1 January 2020
Primary endpoint
30 January 2021
15 May 2021

Quick facts

Lead sponsorHospital Universitari Vall d'Hebron Research Institute
StatusCompleted
Study typeOBSERVATIONAL
Enrollment350
Start date1 January 2020
Primary completion30 January 2021
Estimated completion15 May 2021
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Who can join

Adults 40 to 90, any sex, with Diabetes Mellitus, Type 2 or Catheterization, Peripheral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diabetes Mellitus type 2 (T2DM) is one of the most frequent metabolic diseases worldwide. It is expected that in 2035 around 600 million people will suffer from the disease. A recent systematic review has estimated that the direct annual cost of Diabetes worldwide treatments and care is over $ 827 billion and has been independently associated with nosocomial complications, thrombosis-like infections and prolonged admissions. In addition, it is estimated that up to 90% of patients in acute hospitals require a peripheral venous catheter which are associated at the same time with mechanical, infectious and thrombotic acute complications. Recently the emergence of new medium-sized peripheral devices (Midline®) and new peripheral central venous access catheters (PICC), which are more biocompatible, are opening new clinical possibilities with the aim of improving safety and comfort during treatment time and the reduction of associated complications. With all this, an observational case-control study has been proposed in order to analyse the impact of T2DM disease and its associated complications on the patient requiring peripheral venous access. Furthermore investigators will consider if these new peripheral devices can be a remarkable benefit for these patients. This study will be carried out at the Vall d'Hebron University Hospital in Barcelona, Spain

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

Other Hospital Universitari Vall d'Hebron Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04499638.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing